Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Net Income (2024 - 2025)

Prelude Therapeutics' Net Income history spans 2 years, with the latest figure at -$17.3 million for Q4 2025.

  • For Q4 2025, Net Income rose 48.72% year-over-year to -$17.3 million; the TTM value through Dec 2025 reached -$104.6 million, up 25.16%, while the annual FY2025 figure was -$104.6 million, 25.16% up from the prior year.
  • Net Income for Q4 2025 was -$17.3 million at Prelude Therapeutics, up from -$20.4 million in the prior quarter.
  • Across five years, Net Income topped out at -$17.3 million in Q4 2025 and bottomed at -$37.2 million in Q2 2024.